Bio-Techne appoints Shane Bohnen as SVP, General Counsel; Brenda Furlow retires March 3, 2023

BIO-TECHNE Corp

Shane Bohnen, previously Associate General Counsel since 2019, becomes Senior VP, General Counsel effective March 3, 2023.
Brenda Furlow, EVP & General Counsel for nine years, retires March 3, 2023; will remain as consultant for special projects.
Bohnen's compensation: $331,500 base salary, 50% target cash bonus, one-time $500,000 RSU grant vesting over three years.
Bohnen has over 20 years legal experience including private practice and in-house at Smiths Medical and Resideo.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brenda Furlow

General Counsel

TECH · BIO-TECHNE Corp

Effective: 2023-03-03
Successor: Shane Bohnen
Filed: January 31, 2023, 6:59 PM ET

Mr. Bohnen succeeds Brenda Furlow, who has announced her intention to retire on March 3, 2023.

Appointed

Shane Bohnen

Senior Vice President, General Counsel and Corporate Secretary

TECH · BIO-TECHNE Corp

Effective: 2023-03-03
Filed: January 31, 2023, 6:59 PM ET

appointed Mr. Shane Bohnen, age 48, as an executive officer of the Company in the position of Senior Vice President, General Counsel and Corporate Secretary, effective March 3, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Brenda Furlow retired as general_counsel at BIO-TECHNE Corp.

Action: retired

Exact text from the filing

Mr. Bohnen succeeds Brenda Furlow, who has announced her intention to retire on March 3, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Shane Bohnen was appointed as Senior Vice President, General Counsel and Corporate Secretary at BIO-TECHNE Corp.

Action: appointed
Role: Senior Vice President, General Counsel and Corporate Secretary

Exact text from the filing

appointed Mr. Shane Bohnen, age 48, as an executive officer of the Company in the position of Senior Vice President, General Counsel and Corporate Secretary, effective March 3, 2023.

View on SEC.gov

BIO-TECHNE Corp filing history →

Source: SEC EDGAR

accession 0001558370-23-000715

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.